XML 98 R71.htm IDEA: XBRL DOCUMENT v3.20.4

COMMITMENTS - Agreements to Purchase IP (Details)			12 Months Ended
	Jun. 30, 2014 USD ($)	Aug. 11, 2010 USD ($) item	Dec. 31, 2014 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Oct. 31, 2019 shares	Oct. 17, 2019 USD ($) shares	Dec. 31, 2018 USD ($) shares	Aug. 31, 2018 shares	Mar. 30, 2015 USD ($)
Commercialization rights
Commitments
Commercialization rights at fair value							$ 11,800,000
Australian Asset Purchase Agreement
Commitments
Number of therapeutic candidates | item		3
Upfront initial payment per agreement		$ 500,000	$ 1,000,000
Aggregate payments made				$ 1,500,000
Australian Asset Purchase Agreement | Minimum
Commitments
Percentage of revenues to be paid in the future		7.00%
Australian Asset Purchase Agreement | Maximum
Commitments
Percentage of revenues to be paid in the future		20.00%
Salix Pharmaceuticals, Ltd. Agreement
Commitments
Upfront initial payment per agreement			$ 7,000,000
German Publicly Traded Company Arrangement
Commitments
Upfront initial payment per agreement	$ 1,000,000
German Publicly Traded Company Arrangement | Maximum
Commitments
Royalties percentage	30.00%
U.S. Private Company Arrangement
Commitments
Milestones to be paid										$ 2,000,000
Non-current liability				750,000	$ 500,000			$ 500,000
Aggregate payments made				$ 3,000,000						1,500,000
Cosmo Pharmaceuticals N.V. Strategic Collaboration | Cosmo Pharmaceuticals N.V.
Commitments
Investment in strategic collaboration							36,300,000
Cosmo Pharmaceuticals N.V. Strategic Collaboration | Maximum
Commitments
Commitments in relation to joint ventures							$ 100,000,000
Revenue Milestone | U.S. Private Company Arrangement | Maximum
Commitments
Milestones to be paid										$ 2,000,000
ADSs
Commitments
Number of shares issued | shares								2,857,143	4,166,667
Ordinary shares | Cosmo Pharmaceuticals N.V. Strategic Collaboration | Cosmo Pharmaceuticals N.V.
Commitments
Number of shares issued | shares							5,185,715
Ordinary shares | Cosmo Pharmaceuticals N.V. Strategic Collaboration | Cosmo Technologies Ltd.
Commitments
Number of shares issued | shares							1,714,286
Ordinary shares | ADSs | Cosmo Pharmaceuticals N.V.
Commitments
Number of shares issued | shares						5,185,715
Ordinary shares | ADSs | Cosmo Technologies Ltd.
Commitments
Number of shares issued | shares						1,714,286

X

- Definition

The commitments that the entity has relating to its joint ventures as specified in paragraphs B18-B20 of IFRS 12. [Refer: Joint ventures [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2020-01-01
-Paragraph 23
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_23_a&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_CommitmentsInRelationToJointVentures
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The fair value of financial assets. [Refer: At fair value [member]; Financial assets]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 7
-IssueDate 2020-01-01
-Paragraph 25
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_25&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_FinancialAssetsAtFairValue
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The amount of investments in joint ventures in an entity's separate financial statements. [Refer: Joint ventures [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2020-01-01
-Paragraph 10
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_10&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_InvestmentsInJointVentures
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The amount of non-current contract liabilities. [Refer: Contract liabilities]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2020-01-01
-Paragraph 105
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_105&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_NoncurrentContractLiabilities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The number of shares issued by the entity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 106
-Subparagraph d
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_NumberOfSharesIssued
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Aggregate payments paid to the collaborative partner, as of the balance sheet date.

+ References

No definition available.

+ Details

Name:	rdhl_AggregatePaymentsAsOfReportingPeriod
Namespace Prefix:	rdhl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	rdhl_CollaborativeArrangementsTransactionsLineItems
Namespace Prefix:	rdhl_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Milestone payments to be paid to collaborative partner.

+ References

No definition available.

+ Details

Name:	rdhl_MilestonesToBePaid
Namespace Prefix:	rdhl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Represents the number of therapeutic candidates.

+ References

No definition available.

+ Details

Name:	rdhl_NumberOfTherapeuticCandidates
Namespace Prefix:	rdhl_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The percentage of revenues to be paid to the collaborative partner.

+ References

No definition available.

+ Details

Name:	rdhl_PercentageRevenuesExpectedToBePaid
Namespace Prefix:	rdhl_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the percentage of royalties.

+ References

No definition available.

+ Details

Name:	rdhl_RoyaltiesPercentage
Namespace Prefix:	rdhl_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Upfront arrangement amount paid by the reporting entity to the collaborative partner.

+ References

No definition available.

+ Details

Name:	rdhl_UpfrontInitialPaymentPerAgreement
Namespace Prefix:	rdhl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=rdhl_CommercializationRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	rdhl_TypeOfArrangementTransactionsAxis=rdhl_AustralianAssetPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	rdhl_TypeOfArrangementTransactionsAxis=rdhl_SalixPharmaceuticalsLtd.AgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	rdhl_TypeOfArrangementTransactionsAxis=rdhl_GermanPubliclyTradedCompanyArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	rdhl_TypeOfArrangementTransactionsAxis=rdhl_U.s.PrivateCompanyArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	rdhl_TypeOfArrangementTransactionsAxis=rdhl_CosmoPharmaceuticalsN.v.StrategicCollaborationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=rdhl_CosmoPharmaceuticalsN.v.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	rdhl_MilestoneAxis=rdhl_RevenueMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_ClassesOfOrdinarySharesAxis=rdhl_AmericanDepositorySharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=rdhl_CosmoTechnologiesLtd.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: